Abstract
Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic carbonyls, modulation of retinoic acid level, and regulation of cellular fatty acid synthesis and lipid metabolism. Studies have suggested that AKR1B10 may be a useful biomarker for cancer diagnosis and a potential target for cancer treatment. Over the last decade, a number of AKR1B10 inhibitors including aldose reductase inhibitors (ARIs), endogenous substances, natural-based derivatives and synthetic compounds have been developed, which could be novel anticancer drugs. This review provides an overview on related articles and patents about AKR1B10 inhibitors, with a focus on their inhibition selectivity and mechanism of function.
Keywords: AKR1B10, Aldo-keto reductase, ARL-1, cancer, chemoresistance, inhibitors.
Recent Patents on Anti-Cancer Drug Discovery
Title:Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment
Volume: 11 Issue: 2
Author(s): Li Huang, Rongzhang He, Weihao Luo, Yuan-Shan Zhu, Jia Li, Tan Tan, Xi Zhang, Zheng Hu and Dixian Luo
Affiliation:
Keywords: AKR1B10, Aldo-keto reductase, ARL-1, cancer, chemoresistance, inhibitors.
Abstract: Cytosolic NADPH-dependent reductase AKR1B10 is a member of the aldo-keto reductase (AKR) superfamily. This enzyme is normally expressed in the gastrointestinal tract. However, it is overexpressed in many solid tumors, such as hepatocarcinoma, lung cancer and breast cancer. AKR1B10 may play a role in the formation and development of carcinomas through multiple mechanisms including detoxification of cytotoxic carbonyls, modulation of retinoic acid level, and regulation of cellular fatty acid synthesis and lipid metabolism. Studies have suggested that AKR1B10 may be a useful biomarker for cancer diagnosis and a potential target for cancer treatment. Over the last decade, a number of AKR1B10 inhibitors including aldose reductase inhibitors (ARIs), endogenous substances, natural-based derivatives and synthetic compounds have been developed, which could be novel anticancer drugs. This review provides an overview on related articles and patents about AKR1B10 inhibitors, with a focus on their inhibition selectivity and mechanism of function.
Export Options
About this article
Cite this article as:
Huang Li, He Rongzhang, Luo Weihao, Zhu Yuan-Shan, Li Jia, Tan Tan, Zhang Xi, Hu Zheng and Luo Dixian, Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment, Recent Patents on Anti-Cancer Drug Discovery 2016; 11 (2) . https://dx.doi.org/10.2174/1574892811888160304113346
DOI https://dx.doi.org/10.2174/1574892811888160304113346 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy Meet Our Editorial Board Member
Current Chemical Biology Research Development of End Traction Shoulder Rehabilitation Device
Recent Patents on Mechanical Engineering Cancer Metastasis, a Clinical Dilemma for Therapeutics
Current Drug Therapy Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery
Current Drug Metabolism Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Nutritional Modulation of Terminal End Buds: Its Relevance to Breast Cancer Prevention
Current Cancer Drug Targets Modulation of Doxorubicin Mediated Growth Inhibition of Hepatocellular Carcinoma Cells by Platelet Lysates
Anti-Cancer Agents in Medicinal Chemistry Selective Matrix Metalloproteinase Inhibitors for Cancer
Current Medicinal Chemistry DNA Methylation and Breast Cancer
Current Genomics Molecular and Biological Functions of Melatonin in Endometrial Cancer
Current Drug Targets The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review
Recent Patents on Inflammation & Allergy Drug Discovery Potential Therapeutic Relevance of CRISPR/Cas9 Guided Epigenetic Regulations for Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry The Genetic Landscapes of Inflammation-Driven Gastrointestinal Tract Cancers
Current Pharmaceutical Design Cancer and Cyclooxygenase-2 (COX-2) Inhibition
Current Pharmaceutical Design Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Fgf10: A Paracrine-Signaling Molecule in Development, Disease, and Regenerative Medicine
Current Molecular Medicine siRNA Delivery by Stimuli-Sensitive Nanocarriers
Current Pharmaceutical Design